GSKGLAXF -0.85%75 Forward PE Ratio is 10.48 as of Jun. 30, 2026. GuruFocus rates GLAXF with a GF Score™ of 75/100 and a GF Value™ of $21.13 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 406 Drug Manufacturers companies, GSK ranks better than 71.18% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
GSK Forward PE Ratio Related Terms
GSK Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for GSK's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSK Forward PE Ratio Chart
GSK Annual Data
Trend
2015-12
2016-12
2017-12
2018-12
2019-12
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
16.78
15.08
12.15
13.61
15.06
11.07
13.99
9.84
9.19
7.85
9.26
GSK Quarterly Data
2015-12
2016-03
2016-06
2016-09
2016-12
2017-03
2017-06
2017-09
2017-12
2018-03
2018-06
2018-09
2018-12
2019-03
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
16.78
16.86
15.77
16.18
15.08
15.29
15.02
13.64
12.15
12.82
14.39
14.04
13.61
14.84
14.20
14.14
15.06
12.63
14.01
12.94
11.07
12.79
14.29
11.82
13.99
13.04
13.97
9.90
9.84
9.78
9.49
9.51
9.19
10.80
9.68
8.54
7.85
9.22
8.12
8.41
9.26
11.29
GLAXF vs LLY, JNJ, ABBV: Forward PE Ratio Comparison
For the Drug Manufacturers - General subindustry, GSK's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where GSK's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
GSK (GLAXF) has a Forward PE Ratio of 10.48 as of Jun. 30, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on GSK and its competitors. According to the industry distribution chart, GSK ranks #117 out of 406 companies in the Drug Manufacturers industry, placing it in the top 28.8%.
Is GSK's Forward PE Ratio too high?
GSK's current Forward PE Ratio is 10.48. The Drug Manufacturers industry median Forward PE Ratio is 17.10. GSK's value of 10.48 is 38.7% below this industry median. Based on the distribution chart, GSK ranks #117 out of 406 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GSK has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Forward PE Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #117 out of 406 companies for Forward PE Ratio. This puts GSK in the upper half of its industry. The industry median Forward PE Ratio is 17.10. GSK's value of 10.48 is 38.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.10, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current Forward PE Ratio of 10.48 is 38.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on GSK and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current Forward PE Ratio is 10.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.13, compared to a current price of $25.12 — trading 18.9% above its estimated fair value. The current Forward PE Ratio is 10.48 and 38.7% below the Drug Manufacturers industry median of 17.10. GSK's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For GSK (GLAXF), the current Forward PE Ratio is 10.48 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $25.12 is trading 18.9% above its estimated GF Value™ of $21.13.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
Forward PE Ratio: 10.48
GF Value™: $21.13 vs. price of $25.12 (18.9% above fair value)
Industry Position: 38.7% below the Drug Manufacturers median (#117 of 406)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
75GF Score
Get the complete analysis for GLAXF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 